Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05891834 | Study of INV-202 in Patients With Obesity and Metabolic Syndrome | PHASE2 | COMPLETED | 243 | — | — | Sep 8, 2023 | Feb 14, 2025 | Jun 5, 2025 | 24 | Canada |
Mean change from baseline in body weight at Week 16 for INV-202 versus placebo
| Arm | Type | Description |
|---|---|---|
| Low dose | EXPERIMENTAL | INV-202, 10 mg |
| High dose | EXPERIMENTAL | INV-202, 50 mg |
| Placebo | PLACEBO_COMPARATOR | Placebo Matching size and number of tablets |
| Middle Dose | EXPERIMENTAL | INV-202, 20 mg |
| Name | Type | Description |
|---|---|---|
| INV-202 | DRUG | tablet, once daily, oral |
| Placebo | DRUG | tablet, once daily, oral |
Inclusion Criteria: 1\. Male and female participants from 18 to 75 years of age 2. Able and willing to provide informed consent and to comply with scheduled visits and study procedures 3. BMI ≥ 30 kg/m2 4. Presence of at least 3 of the 5 following criteria at screening: i. Increased waist circumfer...